查看中文
xxu@cooley.com
Xiaoyu Xu focuses her practice in the areas of initial public offerings, venture capital investment, mergers and acquisitions, and general corporate matters.
Download full bio
InnoRNA Collaboration with BeiGene
Keymed Biosciences – HK$3.1 Billion IPO
Capital Markets
Venture Capital
Mergers & Acquisitions
Life Sciences
Asia
Columbia University LLM
University of International Business and EconomicsLLB
New York
Keymed Biosciences – HK$3.1 Billion IPO July 8, 2021
+86 10 8540 0652
Locations